Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

NCT05204862 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: TU2218
DRUG: Anti-PD-1 antibody

Sponsor

TiumBio Co., Ltd.